Last deal

$150M

Amount

Post-IPO Equity

Stage

17.01.2024

Date

3

all rounds

$681.7M

Total amount

date founded

Financing round

General

About Company
Viridian Therapeutics is developing new treatments for serious diseases.

Industry

Sector :

Subsector :

Also Known As

MiRagen Therapeutics

founded date

01.01.2007

Number of employees

Company Type

For Profit

Last funding type

Post-IPO Equity

IPO status

Private

Description

The company's most advanced program, VRDN-001, is a clinical-stage anti-IGF-1R monoclonal antibody being developed for thyroid eye disease (TED). Viridian is headquartered in Boulder, Colorado, with research and development operations in Waltham, Massachusetts. They also have a remote staff across the country. In addition to TED, Viridian has early-stage programs focused on other targets and indications to address unmet medical needs.
Contacts

Contact Email

Phone number

Social url

Similar Companies
1000
Atara Biotherapeutics

Atara Biotherapeutics

Atara Biotherapeutics is developing transformative off-the-shelf therapies for serious diseases.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Keywords

Biotechnology, Health Care, Therapeutics

Location

South San Francisco, CA, USA

total rounds

10

total raised

$535.82M
Lassen Therapeutics

Lassen Therapeutics

Lassen Therapeutics is a developer of antibody biotherapeutics, improving the lives of patients with serious diseases.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Location

San Diego, CA, USA

total rounds

2

total raised

$116M
Pandion Therapeutics

Pandion Therapeutics

Pandion Therapeutics develops novel therapeutics for autoimmune diseases.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Keywords

Biotechnology, Health Care, Therapeutics

Location

Cambridge, MA, USA

total rounds

2

total raised

$138M
Alentis Therapeutics

Alentis Therapeutics

ALENTIS Therapeutics develops new therapies for advanced liver disease and cancer.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Keywords

Biotechnology, Health Care, Therapeutics

Location

Basel, Switzerland

total rounds

4

total raised

$171.17M

Financials

Funding Rounds
13
3

Number of Funding Rounds

$681.7M

Money Raised

Their latest funding was raised on 17.01.2024. Their latest round Post-IPO Equity

Date 
Funding Round 
Investors 
Money Raised 
Lead 
17.01.2024
$150M
30.10.2023
$185M
Hercules Capital

Hercules Capital

Hercules Capital, Inc. provides senior secured venture growth loans to high-growth, innovative venture capital-backed companies.

Sector

Investment Banking and Brokerage Services

Subsector

Diversified Financial Services

Keywords

Financial Services, Venture Capital, Finance

Location

Palo Alto, CA, USA

total rounds

2

total raised

$6.5M

count Of Investments

225

count Of Exists

65
Co-Investors
Investors
12
8

Number of lead investors

12

Number of investors

Investor 
Lead 
Round 
Partners 
Amgen Ventures

Amgen Ventures

Amgen Ventures is a biotech-focused venture capital firm.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Location

San Francisco, CA, USA

count Of Investments

73

count Of Exists

10
Marvin Caruthers

Marvin Caruthers

Marvin Caruthers, Ph.D., is a Distinguished Professor of Chemistry and Biochemistry at the University of Colorado and a pioneer in the biotechnology field. One of the co-founders of Amgen and Applied Biosystems, Caruthers’ groundbreaking scientific research in nucleic acid chemistry led to the development of DNA synthesizing techniques that remain the industry standard today. Caruthers holds a B.S. in Chemistry from Iowa State University and a Ph.D. in Biochemistry from Northwestern University. A Guggenheim Fellow, he is a member of the National Academy of Sciences and the American Academy of Arts and Sciences. Caruthers was awarded the National Medal of Science for 2006, the nation’s highest distinction honoring scientific achievement.

current job

University of Colorado
University of Colorado
Broadview Ventures

Broadview Ventures

Broadview Ventures invests in technology solutions for cardiovascular and neurovascular diseases.

Sector

Medical Equipment and Services

Subsector

Medical Equipment

Keywords

Health Care

Location

Boston, MA, USA

count Of Investments

68

count Of Exists

3
Thomas E. Hughes

Thomas E. Hughes

Dr. Hughes has over 25 years of experience in pharmaceutical research and development. Dr. Hughes joined Zafgen in 2008 as president, chief executive officer and a member of the company’s board of directors. From 1987 to 2008, Dr. Hughes held several positions at Novartis AG (and formerly Sandoz Pharmaceuticals) including vice president and global head of the cardiovascular and metabolic diseases therapeutic area at the Novartis Institutes for BioMedical Research in Cambridge, MA. In these roles he oversaw many drug discovery and development projects targeting obesity, diabetes, and heart disease. As a scientist, Dr. Hughes led Novartis’ efforts to discover and develop its dipeptidylpeptidase IV inhibitor vildagliptin (Galvus®/Eucreas®), a drug used for the treatment of type 2 diabetes, currently approved in 70 countries. Dr. Hughes is the author of over 40 peer-reviewed publications and is an inventor on numerous issued and pending patents related to the treatment of diabetes, cardiovascular disease, and obesity. Dr. Hughes also serves as a director on the board of Miragen Therapeutics, Inc., and is a member of several scientific and strategic advisory boards, including Broadview Ventures and Nimbus Discovery, LLC.

current job

Navitor Pharmaceuticals
Remeditex Ventures

Remeditex Ventures

Remeditex invests in innovative early-stage projects with commercialization potential.

Sector

Investment Banking and Brokerage Services

Subsector

Asset Managers and Custodians

Location

Dallas, TX, USA

count Of Investments

16

count Of Exists

3
Dennis Keith Stone

Dennis Keith Stone

Dennis has served as a member of the Board of Directors since September 2002. Dennis is Chief Scientific Officer and a Director of Remeditex Ventures LLC. He joined Remeditex in August 2011 from UT Southwestern Medical Center, or UTSW, where he was Professor of Internal Medicine, Physiology, and Biochemistry. He served as the Vice President of Technology Development for UTSW from 1998 until July 2011. He has served on the board of directors of Eliance Biotechnologies, Inc., Myogen, Inc., miRagen Therapeutics, Inc., and MacroGenics, Inc. In addition, he served as the Chairman of the UT Regents’ Technology Transfer Commission, and he was vice chairman of the board of the Texas Emerging Technology Fund’s Life Science Commercialization Center. He received his undergraduate training at The University of Texas at Austin and his medical degree from UTSW.

current job

Remeditex Ventures
Remeditex Ventures
Acquisitions
2
Viridian Therapeutics acquired by Viridian Therapeutics

Viridian Therapeutics acquired by Viridian Therapeutics

acquirer

Viridian Therapeutics
Viridian Therapeutics

date

28.10.2020

type

Acquisition
Viridian Therapeutics

Viridian Therapeutics

Viridian Therapeutics develops new treatments for underserved diseases in biotechnology.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Keywords

Biotechnology, Health Care, Therapeutics

Location

Waltham, MA, USA

total rounds

2

total raised

$29M
Signal Genetics acquired by Viridian Therapeutics

Signal Genetics acquired by Viridian Therapeutics

acquirer

Viridian Therapeutics
Viridian Therapeutics

date

02.11.2016

type

Acquisition

price

$60M
Signal Genetics

Signal Genetics

Signal Genetics, Inc. is a molecular diagnostics company that provides innovative diagnostic services for cancer patients.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Keywords

Health Care, Biotechnology, Health Diagnostics

Location

Carlsbad, CA, USA

total rounds

2

total raised

$25M

People

Founders
2
William Marshall
William Marshall

William Marshall

William S. Marshall, Ph.D., is miRagen’s President, Chief Executive Officer, Co-Founder and Director. Prior to establishing miRagen, Dr. Marshall was Vice President of Technology and Business Development for Bioscience at Thermo Fisher Scientific. In this role, he was responsible for leading technology assessment and strategic planning for the Thermo Fisher Biosciences Division, a unit with revenues of approximately $1 billion that manufactures and supplies a wide range of products and services across the general-chemistry and life-sciences arenas. Dr. Marshall was one of the scientific founders of Dharmacon, Inc., which was acquired by Fisher Scientific International, serving as the Executive Vice President for Research and Operations and General Manager. Prior to joining Dharmacon, Dr. Marshall served in many capacities at Amgen, Inc., most recently as Associate Director of Research, Site Head for Research and Head of the Nucleic Acid and Peptide Technology Department. In these positions, he participated in a wide variety of therapeutic development approaches throughout the drug discovery process leading to the development of clinical candidates. Dr. Marshall earned his B.S. in Biochemistry from the University of Wisconsin-Madison and his Ph.D. in Chemistry in the laboratory of Professor Marvin Caruthers at the University of Colorado at Boulder. He is author and co-author of over 50 research papers and 80 patents. Dr. Marshall currently serves on the Board of FluoroFinder, LLC.

current job

Viridian Therapeutics
Viridian Therapeutics

organization founded

2

William Marshall

Eric Newell Olson
Eric Newell Olson

Eric Newell Olson

Eric Newell Olson, Ph.D. is Professor and Chairman of the Department of Molecular Biology at the University of Texas Southwestern Medical Center at Dallas. One of the world’s leading experts in developmental biology of the heart, Dr. Olson currently holds the Robert A. Welch Distinguished Chair in Science, the Annie and Willie Nelson Professorship in Stem Cell Research, and the Pogue Distinguished Chair in Research on Cardiac Birth Defects at UTSWMC. Prior to his appointment in Dallas, Dr. Olson was both a professor of Biochemistry and Molecular Biology as well as Chemistry at the M.D. Anderson Cancer Center in Houston. He holds BA, Ph.D. and honorary doctorate degrees from Wake Forest University in Winston-Salem, NC. Dr. Olson has received numerous domestic and international awards from organizations such as the American Heart Association, the National Institutes of Health, and Columbia and McGill Universities among others. He is a fellow of the American Academy of Arts and Sciences, the U.S. National Academy of Sciences, and the Institute of Medicine of the National Academy of Sciences Dr. Olson seves on numerous Editorial Boards and scientific societies. In 1996, he was founder of Myogen, Inc., a company that was acquired in 2006 by Gilead Sciences.

current job

Lonestar Heart
Lonestar Heart

organization founded

3

Eric Newell Olson

Employee Profiles
17
Carrie Melvin

Carrie Melvin

Chief Operating Officer

Kristian F. Humer

Kristian F. Humer

CFO & Chief Business Officer

Barrett Katz

Barrett Katz

Chief Medical Officer

Scotty Sengsavang

Vp, product and strategy team leader

Eric Lee

Research associate iii

Kim Ebbesen

Senior accountant

Jeff Hatfield

Board director

Paul Rubin

Paul Rubin

Executive Vice-President of Research and Development

Activity

Recent News
16
News Timeline

The graph reveals the ratio (%) of positive news articles in a chosen time range

week